Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
SUPN
#1402
Supernus Pharmaceuticals, Inc.
54.730
0
+0.48%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
+0.48%
Aylık değişim
+10.77%
6 aylık değişim
+1.35%
Yıllık değişim
+1.35%
Önceki kapanış
54.470
0
Open
54.730
0
Bid
Ask
Low
54.730
0
High
54.730
0
Hacim
97
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
SUPN
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
55.22 M
55.81 M
55.99 M
56.07 M
57.34 M
—
Valuation ratios
Enterprise value
1.69 B
1.95 B
1.72 B
1.62 B
2.59 B
7.88 B
Price to earnings ratio
28.61
27.39
29.5
27.41
-140.56
-56.25
Price to sales ratio
2.67
3.06
2.74
2.66
3.95
12.4
Price to cash flow ratio
10.07
11.77
11.15
9.47
37.21
69.6
Price to book ratio
0.46
1.95
0.45
0.43
0.64
3.48
Enterprise value to EBITDA ratio
5.5
3.57
6.84
6.56
17.69
34.66
Profitability ratios
Return on assets %
0.03
0.01
-0.01
-0
0
0
Return on equity %
0.04
0.01
-0.01
-0
0
0
Return on invested capital %
9.81
4.03
0.1
-1.89
9.66
11.91
Gross margin %
89.99
85.01
89.48
89.83
90.13
354.45
Operating margin %
19.66
12.29
-6.85
-5.06
18.71
19.1
EBITDA margin %
51.41
35
27.61
33.13
-5.62
90.12
Net margin %
21.91
8.8
-7.89
-0.7
0.06
0.27
Liquidity ratios
Quick ratio
1.98
2.16
2.26
2.43
1.47
8.32
Current ratio
2.2
2.35
2.44
2.58
1.8
9.16
Inventory turnover
0.27
0.44
0.3
0.36
0.25
1.36
Asset turnover
0.13
0.13
0.11
0.12
0.14
0.5
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.96
0.79
0.55
1.03
-1.1
1.28
EBIT per share
1.26
0.75
0.38
0.59
-0.63
1.08
EBITDA per share
1.62
1.09
0.74
0.97
-0.19
2.6
Total debt per share
—
—
—
—
—
—
Cash per share
0.57
1.24
2.07
2.55
2.7
8.56
Net current asset value per share
11.47
12.26
12.31
13.03
10.58
48.18
Tangible book value per share
6.27
7.09
7.37
8.21
5.47
28.14
Working capital per share
6.25
7.04
7.26
7.98
4.69
26.97
Book value per share
18.05
18.51
18.45
18.77
18.7
74.43
Haberler
TD Cowen, Supernus Pharmaceuticals için hisse hedefini yükseltti
TD Cowen raises Supernus Pharmaceuticals stock price target on Onapgo relaunch
Supernus Pharmaceuticals hissesi 57,76 dolarla zirve yaptı
Supernus Pharmaceuticals stock hits 52-week high at $57.76
Cantor Fitzgerald, Supernus hissesi için Overweight önerisini korudu
Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains
Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates
Supernus kazancı $0,48 ile beklentilere göre daha kötü, kâr ise beklentilere göre yüksek
Supernus earnings missed by $0.48, revenue topped estimates
Supernus 3. çeyrek kârlılık şokunun ardından kazanç testinde
Supernus faces earnings test after Q3 shock to profitability
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q4 Earnings Expected to Decline